SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001144204-17-042102
Filing Date
2017-08-10
Accepted
2017-08-10 17:05:30
Documents
51
Period of Report
2017-08-10

Document Format Files

Seq Description Document Type Size
1 FORM 6-K v472575_6k.htm 6-K 13604
2 EXHIBIT 99.1 v472575_ex99-1.htm EX-99.1 220554
3 EXHIBIT 99.2 v472575_ex99-2.htm EX-99.2 54722
  Complete submission text file 0001144204-17-042102.txt   3592115

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE DOCUMENT aktx-20170630.xml EX-101.INS 927541
5 XBRL TAXONOMY EXTENSION SCHEMA aktx-20170630.xsd EX-101.SCH 31062
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE aktx-20170630_cal.xml EX-101.CAL 23543
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE aktx-20170630_def.xml EX-101.DEF 218269
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE aktx-20170630_lab.xml EX-101.LAB 253460
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aktx-20170630_pre.xml EX-101.PRE 253587
Mailing Address 24 WEST 40TH STREET 8TH FLOOR NEW YORK NY 10018
Business Address 24 WEST 40TH STREET 8TH FLOOR NEW YORK NY 10018 (646) 350-0702
Akari Therapeutics Plc (Filer) CIK: 0001541157 (see all company filings)

IRS No.: 981034922 | State of Incorp.: X0
Type: 6-K | Act: 34 | File No.: 001-36288 | Film No.: 171022191
SIC: 2834 Pharmaceutical Preparations